Insmed Inc (INSM)vsExicure Inc (XCUR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
XCUR
Exicure Inc
$4.61
+3.13%
HEALTHCARE · Cap: $28.49M
Smart Verdict
WallStSmart Research — data-driven comparison
XCUR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
XCUR
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : XCUR
XCUR has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : XCUR
The primary concerns for XCUR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while XCUR is a value play — different risk/reward profiles.
XCUR carries more volatility with a beta of 4.19 — expect wider price swings.
XCUR is growing revenue faster at 9.3% — sustainability is the question.
XCUR generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Exicure Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?